Literature DB >> 20842450

Effects of selected genetic polymorphisms in xeroderma pigmentosum complementary group D on gastric cancer.

Ziping Chen1, Chuanzhen Zhang, Changqing Xu, Kun Li, Ruiping Hou, Danping Li, Xiaoli Cheng.   

Abstract

DNA repair capacity (DRC) can be altered based on sequence variations in DNA repair genes, which may result in cancer susceptibility. The current study was to evaluate the association between genetic polymorphisms, including associated haplotypes of xeroderma pigmentosum complementary group D (XPD), and individual susceptibility to gastric cancer. Two-hundred-eight patients with gastric cancer and 339 healthy controls were enrolled in this study. Their genomic DNA was extracted from peripheral blood leukocytes. The genotypes at exon 6, 10 and 23 were identified by polymerase chain reaction (PCR). Unconditional logistic regression model was used to analyze the effects of the polymorphisms, including the corresponding haplotypes, on the susceptibility to develop gastric cancer. The proportion of genotypes GA or AA at exon 10 in cases was showed to be significantly higher than that in controls (P < 0.01, P < 0.01, respectively). The risk of genotype GA or AA carriers to develop gastric cancer was simultaneously much higher (OR = 3.38, 95% CI 2.30-4.95; OR = 6.13, 95% CI 2.45-15.31, respectively). The allele A at exon 10 was also observed to manifest a substantially higher frequency in cases compared to controls (P < 0.01), which might indicate an increased tendency to gastric cancer (OR = 2.40, 95% CI 1.81-3.17). No significant differences were found in the distribution of genotypes at exon 6 or 23 between the two groups (P = 0.23, P = 0.52; P = 0.44, P = 0.56, respectively). By haplotype analysis, haplotype AAA could individually increase incidence of gastric cancer (P < 0.01, OR = 3.39, 95% CI 2.21-5.21). In contrast, haplotypes CGA and AGA were showed a decline in gastric cancer susceptibility (OR = 0.67, 95% CI 0.46-0.97; OR = 0.58, 95% CI 0.41-0.83, respectively). The rest of haplotypes made no statistically significant difference between cases and controls. Taken together, this study demonstrates that the genetic variation at exon 10 and haplotype AAA may be contributing factors in developing gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20842450     DOI: 10.1007/s11033-010-0258-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  31 in total

1.  Effect of polymorphisms in XPD, RAI, ASE-1 and ERCC1 on the risk of basal cell carcinoma among Caucasians after age 50.

Authors:  Ulla Vogel; Anja Olsen; Håkan Wallin; Kim Overvad; Anne Tjønneland; Bjørn A Nexø
Journal:  Cancer Detect Prev       Date:  2005-04-22

Review 2.  ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review.

Authors:  Simone Benhamou; Alain Sarasin
Journal:  Am J Epidemiol       Date:  2005-01-01       Impact factor: 4.897

3.  An investigation on the polymorphisms of two DNA repair genes and susceptibility to ESCC and GCA of high-incidence region in northern China.

Authors:  Na Wang; Xiu-Juan Dong; Rong-Miao Zhou; Wei Guo; Xiao-Juan Zhang; Yan Li
Journal:  Mol Biol Rep       Date:  2007-11-29       Impact factor: 2.316

4.  The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden.

Authors:  Weimin Ye; Rajiv Kumar; Gabriela Bacova; Jesper Lagergren; Kari Hemminki; Olof Nyrén
Journal:  Carcinogenesis       Date:  2006-03-29       Impact factor: 4.944

Review 5.  ERCC2/XPD gene polymorphisms and cancer risk.

Authors:  Simone Benhamou; Alain Sarasin
Journal:  Mutagenesis       Date:  2002-11       Impact factor: 3.000

6.  The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway.

Authors:  X W Wang; W Vermeulen; J D Coursen; M Gibson; S E Lupold; K Forrester; G Xu; L Elmore; H Yeh; J H Hoeijmakers; C C Harris
Journal:  Genes Dev       Date:  1996-05-15       Impact factor: 11.361

Review 7.  Incidence and mortality of gastric cancer in China.

Authors:  Ling Yang
Journal:  World J Gastroenterol       Date:  2006-01-07       Impact factor: 5.742

8.  Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma.

Authors:  James Doecke; Zhen Zhen Zhao; Nirmala Pandeya; Shahram Sadeghi; Mitchell Stark; Adèle C Green; Nicholas K Hayward; Penelope M Webb; David C Whiteman
Journal:  Int J Cancer       Date:  2008-07-01       Impact factor: 7.396

9.  Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma.

Authors:  M Dybdahl; U Vogel; G Frentz; H Wallin; B A Nexø
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-01       Impact factor: 4.254

10.  [Mechanism of regulation of hepatoma cell cycle by XPD/P44 subcomplex : an in vitro experiment].

Authors:  Hong-yun Wang; Gao-fei Xiong; Bo-lin Wu; Ji-xiang Zhang
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2008-07-22
View more
  4 in total

Review 1.  The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis.

Authors:  Huiping Xue; Yan Lu; Bing Lin; Jinxian Chen; Feng Tang; Gang Huang
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

Review 2.  Association between the ERCC2 Asp312Asn polymorphism and risk of cancer.

Authors:  Feifan Xiao; Jian Pu; Qiongxian Wen; Qin Huang; Qinle Zhang; Birong Huang; Shanshan Huang; Aihua Lan; Yuening Zhang; Jiatong Li; Dong Zhao; Jing Shen; Huayu Wu; Yan He; Hongtao Li; Xiaoli Yang
Journal:  Oncotarget       Date:  2017-07-18

3.  Lack of association between the XPD Lys751Gln polymorphism and colorectal cancer risk: a meta-analysis.

Authors:  Tao Zhang; Dong-Ming Zhang; Da Zhao; Xiao-Ming Hou; Shou-Cheng Ma; Xiao-Jun Liu
Journal:  Onco Targets Ther       Date:  2014-07-12       Impact factor: 4.147

4.  Association of nucleotide excision repair pathway gene polymorphisms with gastric cancer and atrophic gastritis risks.

Authors:  Jingwei Liu; Liping Sun; Qian Xu; Huakang Tu; Caiyun He; Chengzhong Xing; Yuan Yuan
Journal:  Oncotarget       Date:  2016-02-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.